See participant list See Backgrounder Summary Welcome (Bob Carter, 0:00 1) Dr. Carter provided an overview of why NIAMS was holding this meeting (see background), acknowledged key staff who were involved in its development, and urged participants to keep the discussions focused on the scientific needs and opportunities related to subset analysis in clinical studies. He asked everyone to think broadly about how the various statistical approaches could be applied to NIAMS mission areas and to share their contributions during the afternoon discussion. 1 Times are noted in approximate hours and minutes on the videocast. The link does not take

Scientists can distinguish between highly similar cell types using cutting-edge laboratory procedures. Using such techniques, IRP researchers have identified a particular variety of cell in a specific stage of its life cycle as a primary culprit behind the autoimmune disease known as lupus.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) appointed Gayle Lester, Ph.D., as the director of the Division of Extramural Research. Lester had held the position in an acting role since the reorganization of the Institute's extramural program in April 2018. She assumed the director position March 1, 2020 and will continue to oversee both DER and the Office of Extramural Operations (OEO). "Gayle has provided strong leadership during her time as acting head of DER, and I look forward to watching our extramural efforts continue to prosper," Robert H. Carter, M.D., acting director at NIAMS, said

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) appointed Robert A. Colbert, M.D., Ph.D., as the director of the Institute's Clinical Research Program on February 16, 2020. Colbert, who joined the NIAMS in 2008, had served as deputy clinical director since 2012 and as acting clinical director since June 2018. "What excites me about the NIAMS Clinical Research Program director position is the opportunity we have to make an impact," Colbert explained. "We have a number of research programs that are making new discoveries that reveal how diseases develop and evolve and are translating these discoveries into

Researchers at the National Institutes of Health have discovered a second gene that causes melorheostosis, a rare group of conditions involving an often painful and disfiguring overgrowth of bone tissue. The gene, SMAD3, is part of a pathway that regulates cell development and growth. The researchers are now working to develop an animal model with a mutant version of SMAD3 to test potential treatments for the condition. The study appears in the Journal of Experimental Medicine.